肾炎康复片联合他克莫司治疗肾病综合征的临床研究
|
摘要
目的研究肾炎康复片联合他克莫司胶囊治疗肾病综合征的临床疗效。方法选取2016年8月—2018年8月三二〇一医院收治的肾病综合征患者60例为研究对象,将所有患者采用照抽签方式分为对照组和治疗组,每组各30例。对照组患者口服他克莫司胶囊,0.05mg/(kg·d),保持他克莫司血药浓度为10ng/m L;治疗组在对照组治疗的基础上口服肾炎康复片,5片/次,3次/d。两组持续治疗2个月。观察两组患者的临床疗效,比较两组治疗前后的肾功能指标和血清炎症因子水平。结果治疗后,治疗组总有效率为93.33%,显著高于对照组的76.67%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血浆白蛋白(ALB)水平显著升高,24 h尿蛋白定量(24 h Pro)、血肌酐(Scr)和血尿素氮(BUN)水平显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组肾功能指标显著优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者C-反应蛋白(CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组血清炎症因子水平明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论肾炎康复片联合他克莫司胶囊治疗肾病综合征具有较好的临床疗效,可显著改善患者肾功能,安全性较高,具有一定的临床推广应用价值。
objective To study the clinical effect of Shenyan Kangfu Tablets combined with Tacrolimus Capsules in treatment of nephrotic syndrome. Methods Patients(60 cases) with nephrotic syndrome in San Er Ling Yi Hospital from August 2016 to August2018 were divided into control and treatment groups by lottery, and each group had 30 cases. Patients in the control group were po administered with Tacrolimus Capsules, 0.05 mg/(kg·d), and the blood concentration of tacrolimus was maintained at 10 ng/mL.Patients in the treatment group were po administered with Shenyan Kangfu Tablets on the basis of control group, 5 tablets/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the renal function indexes and serum inflammatory factors levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 93.33%, which was significantly higher than 76.67% in the control group,and there were differences between two groups(P < 0.05). After treatment, ALB levels in two groups were significantly increased, but the 24 h Pro, Scr, and BUN levels were decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the renal function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of CRP, IL-6, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, serum inflammatory factors levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Shenyan Kangfu Tablets combined with Tacrolimus Capsules has a good clinical effect in treatment of nephrotic syndrome, can significantly improve the renal function, with high safety, which has a certain clinical application value.
objective To study the clinical effect of Shenyan Kangfu Tablets combined with Tacrolimus Capsules in treatment of nephrotic syndrome. Methods Patients(60 cases) with nephrotic syndrome in San Er Ling Yi Hospital from August 2016 to August2018 were divided into control and treatment groups by lottery, and each group had 30 cases. Patients in the control group were po administered with Tacrolimus Capsules, 0.05 mg/(kg·d), and the blood concentration of tacrolimus was maintained at 10 ng/mL.Patients in the treatment group were po administered with Shenyan Kangfu Tablets on the basis of control group, 5 tablets/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the renal function indexes and serum inflammatory factors levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 93.33%, which was significantly higher than 76.67% in the control group,and there were differences between two groups(P < 0.05). After treatment, ALB levels in two groups were significantly increased, but the 24 h Pro, Scr, and BUN levels were decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the renal function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of CRP, IL-6, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, serum inflammatory factors levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Shenyan Kangfu Tablets combined with Tacrolimus Capsules has a good clinical effect in treatment of nephrotic syndrome, can significantly improve the renal function, with high safety, which has a certain clinical application value.
引文
[1]郝静,袁伟杰.难治性肾病综合征的病因及治疗研究进展[J].中国中西医结合肾病杂志,2013,14(6):553-555.
[2]叶琨,王浩宇,徐珏,等.他克莫司联合糖皮质激素治疗难治性肾病综合征的临床评估[J].实用医学杂志,2013,29(9):1500-1502.
[3]赵亚清.肾炎康复片和雷公藤多甙片联合治疗难治性肾病综合征的疗效观察[J].中国中西医结合肾病杂志,2004,5(12):725-726.
[4]叶任高.中西医结合肾脏病学[M].北京:人民卫生出版社,2003:208-248.
[5]孙传兴.临床疾病诊断依据治愈好转标准[M].第2版.北京:人民军医出版社出版,2002:134.
[6]林丽,钟飞,杨树升.原发性肾病综合征发生机制的研究进展[J].湖南中医药大学学报,2003,23(1):62-64.
[7]关欣,郑红光,霍平,等.他克莫司对难治性肾病综合征患者临床疗效的影响[J].贵阳医学院学报,2012,37(5):535-537.
[8]殷士涛,彭月萍.肾炎康复片联合坎地沙坦治疗原发性肾病综合征临床观察[J].北京中医药,2012,31(7):539-541.
[9]向代军,王成彬,马骏龙,等.血清C反应蛋白、纤维蛋白原与原发性肾病综合征相关分析[J].解放军医学院学报,2013,34(2):124-125.
[10]王汉民,李锋,刘亚玲,等.不同病理类型肾病综合征患者血清IL-6、IL-8及TNF-α水平的变化[J].现代医学,2004,32(3):173-175.
[2]叶琨,王浩宇,徐珏,等.他克莫司联合糖皮质激素治疗难治性肾病综合征的临床评估[J].实用医学杂志,2013,29(9):1500-1502.
[3]赵亚清.肾炎康复片和雷公藤多甙片联合治疗难治性肾病综合征的疗效观察[J].中国中西医结合肾病杂志,2004,5(12):725-726.
[4]叶任高.中西医结合肾脏病学[M].北京:人民卫生出版社,2003:208-248.
[5]孙传兴.临床疾病诊断依据治愈好转标准[M].第2版.北京:人民军医出版社出版,2002:134.
[6]林丽,钟飞,杨树升.原发性肾病综合征发生机制的研究进展[J].湖南中医药大学学报,2003,23(1):62-64.
[7]关欣,郑红光,霍平,等.他克莫司对难治性肾病综合征患者临床疗效的影响[J].贵阳医学院学报,2012,37(5):535-537.
[8]殷士涛,彭月萍.肾炎康复片联合坎地沙坦治疗原发性肾病综合征临床观察[J].北京中医药,2012,31(7):539-541.
[9]向代军,王成彬,马骏龙,等.血清C反应蛋白、纤维蛋白原与原发性肾病综合征相关分析[J].解放军医学院学报,2013,34(2):124-125.
[10]王汉民,李锋,刘亚玲,等.不同病理类型肾病综合征患者血清IL-6、IL-8及TNF-α水平的变化[J].现代医学,2004,32(3):173-175.